Transdermal Drug Delivery Systems Market Growth Factors, Segmentation, Trends, Opportunities, Key Players and Forecast | Evolve Business Intelligence

Key Highlights:
• The global Transdermal Drug Delivery Systems Market size was valued at USD 31.9 billion in 2022 growing at a CAGR of 5.3% from 2023 to 2033.
• North America dominated the market in 2022
• Asia Pacific is expected to grow at the highest CAGR from 2023 to 2033

As per the study initiated by Evolve Business Intelligence, the global Transdermal Drug Delivery Systems Market size accounted for USD 31.9 Billion in 2022, growing at a CAGR of 5.3% from 2023 to 2033. The Transdermal Drug Delivery Systems (TDDS) market refers to the industry involved in the development, manufacturing, and distribution of pharmaceutical products designed to deliver therapeutic agents through the skin and into the bloodstream. Transdermal drug delivery is an alternative to traditional oral or injectable routes, offering advantages such as sustained release, improved patient compliance, and reduced side effects.

Request/Download PDF Sample: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021401

The Transdermal Drug Delivery Systems Market is primarily driven by the Rising Prevalence of Chronic Diseases. The increasing incidence of chronic diseases such as cardiovascular disorders, diabetes, and pain-related conditions has driven the demand for effective and continuous drug delivery. Transdermal patches provide a viable solution for managing these chronic conditions.

Key Players
Some of the major Transdermal Drug Delivery Systems Market players holding high market shares include Mylan NV., Hisamitsu Pharmaceutical Co. Inc., Novartis International AG, Boehringer Ingelheim International GmbH and GlaxoSmithKline PLC. These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders. Some of the other major market players include Pfizer Inc., Allergan plc, Actelion Pharmaceuticals Ltd and Noven Pharmaceuticals.

For More Information: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021401

Segmental Analysis
Based on Product, the Transdermal Drug Delivery Systems Market is segmented into Transdermal Patches and Semisolids. transdermal patches and semisolids. The transdermal patches segment held the majority share. This is primarily due to the emergence of technological innovations, such as the inclusion of microneedles or mechanical arrays in transdermal patches. However, semisolids is the fastest-growing category over the forecast period due to the growing emphasis on implementing inorganic strategies to elevate manufacturing capacity.
Based on Technology, the Transdermal Drug Delivery Systems Market is segmented into Electric Current, Iontophoresis, Electroporation, Ultrasound and Microporation. The iontophoresis segment dominated the market owing to technological advancements. It promotes the movement of ions across the membrane under the influence of a small externally applied potential difference, which has been proven to enhance skin penetration and increase the release rate of several transdermal drug delivery systems with poor absorption/permeation profiles.

Key Region/ Countries Covered
• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Russia, Nordic Countries, BeNeLux, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Rest of Asia Pacific)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA)
• Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from fortune's global 2000 companies.

This release was published on openPR.